Press release from PR Newswire
Questcor to Present at the Maxim Group Growth Conference
Tuesday, November 16, 2010
Questcor to Present at the Maxim Group Growth Conference06:30 EST Tuesday, November 16, 2010ANAHEIM, Calif., Nov. 16, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the Maxim Group Growth Conference at 4:00 p.m. ET on Thursday, November 18, 2010 at the Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments.Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available for 90 days after the live presentation, and can also be accessed at www.questcor.com.About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age. Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors, Gregory Gin or Doug Sherk, both of EVC Group, +1-415-896-6820; or Media, Janine McCargo, +1-646-688-0425, all for Questcor Pharmaceuticals, Inc.